PT - JOURNAL ARTICLE AU - Fasching, Clare L. AU - Servellita, Venice AU - McKay, Bridget AU - Nagesh, Vaishnavi AU - Broughton, James P. AU - Brazer, Noah AU - Wang, Baolin AU - Sotomayor-Gonzalez, Alicia AU - Reyes, Kevin AU - Streithorst, Jessica AU - Deraney, Rachel N. AU - Stanfield, Emma AU - Hendriks, Carley G. AU - Miller, Steve AU - Ching, Jesus AU - Chen, Janice S. AU - Chiu, Charles Y. TI - COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme AID - 10.1101/2021.11.29.21267041 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.29.21267041 4099 - http://medrxiv.org/content/early/2021/11/30/2021.11.29.21267041.short 4100 - http://medrxiv.org/content/early/2021/11/30/2021.11.29.21267041.full AB - Laboratory tests for the accurate and rapid identification of SARS-CoV-2 variants have the potential to guide the treatment of COVID-19 patients and inform infection control and public health surveillance efforts. Here we present the development and validation of a COVID-19 variant DETECTR® assay incorporating loop-mediated isothermal amplification (LAMP) followed by CRISPR-Cas12 based identification of single nucleotide polymorphism (SNP) mutations in the SARS-CoV-2 spike (S) gene. This assay targets the L452R, E484K, and N501Y mutations associated with nearly all circulating viral lineages. In a comparison of three different Cas12 enzymes, only the newly identified enzyme CasDx1 was able to accurately identify all three targeted SNP mutations. We developed a data analysis pipeline for CRISPR-based SNP identification using the assay from 91 clinical samples (Ct < 30), yielding an overall SNP concordance and agreement with SARS-CoV-2 lineage classification of 100% compared to viral whole-genome sequencing. These findings highlight the potential utility of CRISPR-based mutation detection for clinical and public health diagnostics.Competing Interest StatementC.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center and receives research support from Abbott Laboratories, Inc. C.L.F., B.M., V.N., J.P.B., R.N.D., E.S., C.G.H., J.C., and J.S.C. are employees of Mammoth Biosciences. C.Y.C. is a member of the scientific advisory board for Mammoth Biosciences. The other authors declare no competing interests.Funding StatementThis work has been funded by the Innovative Genomics Institute (IGI) at UC Berkeley and UC San Francisco (C.Y.C.), the Sandler Program for Breakthrough Biomedical Research (C.Y.C.), US Centers for Disease Control and Prevention contract 75D30121C10991 (C.Y.C.), and Mammoth Biosciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Remnant nasopharyngeal and/or oropharyngeal (NP/OP) samples and plasma samples from laboratory confirmed SARS-CoV-2 positive patients were retrieved from the UCSF Clinical Laboratories and stored in a biorepository until processed. Remnant sample biobanking was performed with a waiver of consent and according to no-subject contact study protocols approved by the UCSF Institutional Review Board (protocol numbers 10-01116 and 11-05519).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The CasDx1 protein can be provided by Mammoth Biosciences to the extent feasible, pending scientific review and a completed material transfer agreement. Requests for the CasDx1 protein should be submitted to Janice Chen at janice{at}mammothbiosci.com.